Skip to main content

Table 1 Patients and disease characteristics

From: Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system

Number of patients and spinal metastases 32 and 54
Sex (F/M) 11/21
Median age (range) 68 (43–83 years)
Median performance status (range) 1 (0–2)
Histology (%)
 Lung 2 (6.2%)
 Breast 9 (28.1%)
 Prostate 15 (46.9%)
 Others 6 (18.8%)
Median number of spinal metastases (range) 1 (1–3)
Pre-treatment MRI 5 (15.6%)
Pre-treatment PET-CT 22 (68.8%)
Pre-treatment combined radiological exams 5 (15.6%)
Vertebra (%)
 Cervical 7 (13.0%)
 Dorsal 36 (66.7%)
 Lumbar 11 (20.3%)
 Sacral 0
Anatomical site (%)
 Vertebral body 27 (50%)
 Vertebral body + spinal process 1 (1.9%)
 Vertebra body + peduncle 8 (14.8%)
 Vertebral body + spinal process + peduncle 4 (7.4%)
 Peduncle 8 (14.8%)
 Spinal process 4 (7.4%)
 Full vertebra 2 (3.7%)
Spinal Instability Neoplastic Score (SINS)
 Median (range) 5
 0–6 22 (68.7%)
 7–12 10 (31.3%)
Pre-treatment Visual Analogue Scale (VAS)
 Median (range) 0 (range 0–8)
 VAS at first follow-up 0 (range 0–7)
 VAS at Post-treatment
Median (range) 0 (range 0–7)
Systemic therapy combined with SBRT (no; %)
 None 8 (25.0%)
 Hormone therapy 16 (50%)
 Chemotherapy 4 (12.5%)
 Target therapy 0
 Immunotherapy 4 (12.5%)